Imovax Polio

Prevention of poliomyelitis in infants, childn & adults for primary & booster vaccination.

IM/SC Primary vaccination From 2 mth of age 3 successive inj of 0.5 mL at 1-2 mth intervals. 1st booster Administer 12 mth after last dose. Subsequent boosters Adult Inj every 10 yr. Childn & adolescent Inj every 5 yr.

Hypersensitivity to inactivated poliomyelitis virus vaccine; neomycin, streptomycin or polymyxin B. Postpone vaccination in case of fever or acute illness.

Appropriate medical treatment must be available & provide close supervision if rare anaphylactic reactions occur following vaccination. Do not administer intravascularly. Individuals w/ thrombocytopenia or bleeding disorders. May induce reduced immune response during immunosuppressive treatment or immunodeficiency condition; wait until the end of treatment before vaccinating. May recommended in individuals whom oral vaccine is contraindicated, & as booster for those previously vaccinated w/ oral vaccine. Syncope may occur; place procedures to prevent injury due to fainting. Contains phenylalanine which may be dangerous for patients w/ phenylketonuria; ethanol 2 mg/dose & Na 23 mg/dose. May be prescribed during pregnancy in high risk situations. Consider potential risk of apnoea & need for resp monitoring for 48-72 hr when administering primary immunisation series to very premature infants (≤28 wk of gestation) & particularly for those w/ history of resp immaturity.

Inj-site pain, fever (>38.1°C). Inj-site redness.

Use different syringes & separate inj sites in case of concomitant administration w/ other vaccines.

Vaccines, Antisera & Immunologicals

J07BF03 - poliomyelitis, trivalent, inactivated, whole virus ; Belongs to the class of poliomyelitis viral vaccines.

POM